|Articles|September 29, 2017
Ending DIR Fees Could Save Medicare Billions Tops SPT Week in Review
Author(s)Specialty Pharmacy Times Staff
Top news of the week from Specialty Pharmacy Times.
Advertisement
5. It’s Not ‘Just A Uterine Fibroid’
In part 1 of 2, Beth Wallace shares her journey leading up to her diagnosis with leiomyosarcoma.
4. Rapid Hepatitis C Testing Improves Quality of Life Among Young Adults
Same-day results increase the number of individuals who get tested and treated for HCV.
3. FDA Approves Abemaciclib for Advanced, Metastatic Breast Cancer
Verzenio can be administered as a stand-alone treatment to patients previously treated with endocrine therapy and chemotherapy.
2. Humira Litigation Comes to a Close, Clearing Path to Biosimilar Launch
AbbVie grants commercialization rights to Amjevita.
1. Study: Ending DIR Fees Could Save Medicare Billions
The Improving Transparency and Accuracy in Medicare Part D Spending Act would end direct and indirect remuneration fees.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
3
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
4
Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum
5
